Patients with atrial fibrillation needing stroke prevention assigned to abelacimab had very low rates of bleeding during invasive procedures, according to new data from the AZALEA-TIMI 71 trial.The results suggest that patients may not need to stop abelacimab (Anthos Therapeutics), a novel factor XI inhibitor, prior to all invasive procedures, Siddharth Patel, MD, investigator from the TIMI Study
A fifth of four to five-year-olds in England are obese, with parents possibly contributing by giving them portions that are too big
Vaccines for Covid-19: A Personal Reflection by Robert M. Califf, MD
Vaccines for Covid-19: A Personal Reflection by Robert M. Califf, MD
Right ventricular (RV) dyssynchrony or post systolic contraction (PSC) causes inefficient pumping and has not been investigated as a prognostic marker in pulmonary arterial hypertension…
Now that the 119th Congress has convened in Washington, DC, it’s time to continue our efforts in educating both new and returning lawmakers about our…
This economic evaluation analyzes retrospective and prospective data in 9 quality measures to determine their value in improving care for patients who have had a…
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according…
More men with limited life expectancy and certain localized prostate cancers have received definitive treatment over the past 2 decades despite shifts toward active surveillance,…
The two-tiered classification focuses on preclinical and clinical stages of disease, and should help inform treatment decisions.
د. مجدي يعقوب يحسم جدل التجارب السريرية لصمامه الجديد: شغالين في انجلترا مع FDA وطلبوا نمد التجارب لمدة سنة.. والصمام الجديد هيكون جاهز بعد نجاح…
